Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in therapy for chronic hepatitis C.

M W Fried1

  • 1Division of Digestive Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. mfried@med.unc.edu

Clinics in Liver Disease
|November 1, 2001
PubMed
Summary

New treatments combining PEG-IFN and ribavirin offer sustained virologic response rates over 50% for chronic hepatitis C. This marks a significant advance, providing more effective options for patients and guiding future treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.

Alimentary pharmacology & therapeutics·2018
Same author

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.

Alimentary pharmacology & therapeutics·2016
Same author

Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.

Alimentary pharmacology & therapeutics·2015
Same author

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.

Alimentary pharmacology & therapeutics·2015
Same author

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.

Journal of viral hepatitis·2014

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Pharmacology

Background:

  • Chronic hepatitis C treatment has seen significant progress.
  • Previous treatments had limited long-term efficacy.

Purpose of the Study:

  • To highlight the new standard of care for chronic hepatitis C.
  • To discuss the implications of improved sustained virologic response rates.

Main Methods:

  • Review of clinical trial data for new hepatitis C therapies.
  • Analysis of combination therapy with PEG-IFN and ribavirin.

Main Results:

  • Sustained virologic response rates exceeding 50% are achievable.
  • PEG-IFN in combination with ribavirin is emerging as the standard of care.

Related Experiment Videos

Conclusions:

  • Hepatitis C treatment now offers a choice of effective medications.
  • Further data will refine treatment indications and optimize patient care.